SUBSCRIBE
SUBSCRIBE

Phase 1

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Vical Herpes Vaccine Clinical Trial Disappoints with “Confounding Results”
June 23, 2015
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
FDA Grants Breakthrough Designation to Genzyme’s Experimental ASMD Treatment
June 4, 2015
 · 
2 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15 EXCLUSIVE: Berg’s Lead Cancer Drug May Shift Cancer Metabolism, Says CEO
June 3, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
EXCLUSIVE: Nektar Therapeutics, University of Texas MD Anderson Cancer Center Team Up on Phase 1/2 Trial of NKTR-214
June 2, 2015
 · 
5 min read
ASCO15: Bristol Myers Cancer Drug Combo Shrinks 60% of Melanomas, As Oncology Roars
Drug Development
ASCO15: Analyst Calls ImmunoGen’s Phase I Ovarian Cancer Data “Impressive”
June 1, 2015
 · 
4 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Stock Soars as bluebird bio Gives Sneak Peek at Promising Sickle Cell Data
May 21, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
Johnson & Johnson Announced 10 New Approval Applications with $1 Billion Revenue Potential Each
May 20, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech Lung Cancer Treatments Shrink Tumors, Prolong Life
May 14, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
TetraLogic Pharmaceuticals’s New IPO Takes A Hit As Company Halts Hepatitis B Trial
May 6, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
ImmunoGen Has Good News, Bad News as Sanofi SAAR3419 Deal Falls Apart and Ovarian Cancer Treatment Moves Forward
April 28, 2015
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
/C O R R E C T I O N -- Skyhawk Therapeutics/
May 18, 2026
 · 
2 min read
Press Releases
Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule
May 18, 2026
 · 
1 min read
Press Releases
Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026
May 18, 2026
 · 
2 min read
Press Releases
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
May 18, 2026
 · 
6 min read
Press Releases
Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial
May 18, 2026
 · 
3 min read
Press Releases
Earendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)
May 18, 2026
 · 
2 min read
Press Releases
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
May 18, 2026
 · 
3 min read
Press Releases
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
May 18, 2026
 · 
8 min read
Press Releases
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
May 18, 2026
 · 
4 min read
Press Releases
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy
May 18, 2026
 · 
2 min read
Press Releases
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
May 17, 2026
 · 
1 min read
Press Releases
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
May 17, 2026
 · 
9 min read
Press Releases
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
May 17, 2026
 · 
4 min read
Press Releases
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
May 15, 2026
 · 
13 min read
Press Releases
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of ‘SNB-101'
May 14, 2026
 · 
2 min read
Press Releases
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
May 14, 2026
 · 
7 min read
Press Releases
Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026
May 14, 2026
 · 
3 min read
Press Releases
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
May 14, 2026
 · 
11 min read
Press Releases
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
May 14, 2026
 · 
6 min read
Press Releases
Forward Therapeutics Announces Completion of Phase 1 Trials with Two Internally Discovered Next-Generation TNF Signaling Inhibitors Supporting Advancement to Phase 2 Clinical Development
May 14, 2026
 · 
3 min read
Load More